Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis

Bergvall Niklas; Lahoz Raquel; Reynolds Tracy; Korn Jonathan R.

首页> 外文期刊>Current medical research and opinion >Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis

【24h】

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis

机译：芬戈莫德和那他珠单抗治疗多发性硬化症的医疗资源使用和复发：美国一项回顾性索赔数据库分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective:

机译：目的：

著录项

来源
《Current medical research and opinion》 |2014年第8期|共11页
作者
Bergvall Niklas; Lahoz Raquel; Reynolds Tracy; Korn Jonathan R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
Administrative claims; Effectiveness; Fingolimod; Healthcare resource; Multiple sclerosis; Natalizumab; Relapses;

机译：行政索赔;有效性;芬戈莫德;卫生保健资源;多发性硬化症;那他珠单抗;复发;

相似文献

外文文献
中文文献
专利

1. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis [J] . Bergvall Niklas, Lahoz Raquel, Reynolds Tracy, Current medical research and opinion . 2014,第8期

机译：芬戈莫德和那他珠单抗治疗多发性硬化症的医疗资源使用和复发：美国一项回顾性索赔数据库分析
2. Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis [J] . Fox Edward, Vieira Maria Cecilia, Johnson Kristen, Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology . 2019,第期

机译：多发性硬化症患者复发率降低的现实世界耐久性，最长3年：回顾性美国索赔数据库分析
3. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis [J] . Lorscheider Johannes, Benkert Pascal, Lienert Carmen, Multiple sclerosis: clinical and laboratory research . 2018,第6期

机译：Natalizumab与Fingolimod的比较分析作为延迟多发性硬化的二线治疗
4. Microstructural Modulations in the Hippocampus Allow to Characterizing Relapsing-Remitting Versus Primary Progressive Multiple Sclerosis [C] . Lorenza Brusini, Ilaria Boscolo Galazzo, Muge Akinci, International Workshop on Brain-Lesion;Medical Image Computing and Computer Assisted Intervention Conference . 2020

机译：海马中的微观结构调制允许表征复发 - 延长与初级进步多发性硬化
5. Fingolimod (Gilenya; FTY720): A recently approved multiple sclerosis drug based on a fungal secondary metabolite and the creation of a natural products pure compound database and organized storage system. [D] . Strader, Cherilyn R. 2012

机译：芬戈莫德（芬戈莫德； FTY720）：一种最近批准的多发性硬化症药物，它基于真菌的次生代谢产物，并创建了天然产物纯化合物数据库和有组织的存储系统。
6. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials [O] . Georgios Tsivgoulis, Aristeidis H. Katsanos, Dimitris Mavridis, -1

机译：纳他珠单抗与芬戈莫德治疗复发缓解型多发性硬化症的疗效：系统评价随机安慰剂对照试验的间接证据和观察性头对头试验的荟萃分析。
7. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. [O] . Georgios Tsivgoulis, Aristeidis H Katsanos, Dimitris Mavridis, 2016

机译：纳他珠单抗与芬戈莫德对复发缓解型多发性硬化患者的疗效：系统评价，随机安慰剂对照试验的间接证据和观察性头对头试验的meta分析。

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis

摘要

著录项

相似文献

相关主题

期刊订阅